000141816 001__ 141816
000141816 005__ 20240229112527.0
000141816 0247_ $$2doi$$a10.1177/0300891618811273
000141816 0247_ $$2pmid$$apmid:30484384
000141816 0247_ $$2ISSN$$a0300-8916
000141816 0247_ $$2ISSN$$a2038-2529
000141816 0247_ $$2altmetric$$aaltmetric:93531706
000141816 037__ $$aDKFZ-2018-02084
000141816 041__ $$aeng
000141816 082__ $$a610
000141816 1001_ $$aKoerber, Stefan A$$b0
000141816 245__ $$aChemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects.
000141816 260__ $$aThousand Oaks, Calif.$$bSage$$c2019
000141816 3367_ $$2DRIVER$$aarticle
000141816 3367_ $$2DataCite$$aOutput Types/Journal article
000141816 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1555317996_7657
000141816 3367_ $$2BibTeX$$aARTICLE
000141816 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141816 3367_ $$00$$2EndNote$$aJournal Article
000141816 520__ $$aWe evaluated acute and chronic side effects of 3D conformal radiotherapy (3D-CRT) and intensity-modulated radiation therapy (IMRT) in female patients with anal carcinoma and accessed correlations between dosimetric parameters and the considered toxicities.For 70 women with anal cancer treated at our department, acute and chronic side effects and quality of life (QoL) were evaluated with questionnaires using the Common Terminology Criteria for Adverse Events (CTCAE v. 4.0.) and Late Effects in Normal Tissue, Subjective, Objective Management and Analytic Scales (LentSoma) before, during, and after the treatment.Forty-seven out of 70 (67%) patients completed the questionnaire and were enrolled in the study. Only poor urinary stream, loss of pubic hair during chemoradiation, and chronic vaginal dryness were observed more frequently in the 3D-CRT group compared to the IMRT group (univariable logistic regression p = .032, p = .04, p = .049, respectively). After the treatment, 43% in the 3D-CRT group and 29% in the IMRT group reported a severe loss of QoL. A higher proportion among the patients receiving a genital V20 ⩾35% showed grade 1-3 side effects such as chronic dyspareunia ( p = .035; Fisher exact test).Our results suggest that the use of IMRT decreases acute and chronic adverse effects although reduced QoL also occurred in the IMRT group. These effects are likely to be underreported in retrospective studies using physician-reported outcome measures.
000141816 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141816 588__ $$aDataset connected to CrossRef, PubMed,
000141816 7001_ $$aSeither, Ben$$b1
000141816 7001_ $$0P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8$$aSlynko, Alla$$b2$$udkfz
000141816 7001_ $$aHaefner, Matthias F$$b3
000141816 7001_ $$aKrug, David$$b4
000141816 7001_ $$aLiermann, Jakob$$b5
000141816 7001_ $$aAdeberg, Sebastian$$b6
000141816 7001_ $$aHerfarth, Klaus$$b7
000141816 7001_ $$aDebus, Juergen$$b8
000141816 7001_ $$aSterzing, Florian$$b9
000141816 773__ $$0PERI:(DE-600)2267832-3$$a10.1177/0300891618811273$$gp. 030089161881127 -$$n2$$p174-180$$tTumori journal$$v105$$x2038-2529$$y2019
000141816 909CO $$ooai:inrepo02.dkfz.de:141816$$pVDB
000141816 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141816 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141816 9141_ $$y2019
000141816 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTUMORI J : 2017
000141816 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141816 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141816 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141816 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141816 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141816 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141816 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141816 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141816 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141816 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141816 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000141816 980__ $$ajournal
000141816 980__ $$aVDB
000141816 980__ $$aI:(DE-He78)C060-20160331
000141816 980__ $$aUNRESTRICTED